ReShape Lifesciences Inc.

ReShape Lifesciences operated at the intersection of bariatric medical devices, digital weight management, and neuromodulation rather than competing solely as a pharmaceutical obesity company. Its core portfolio included the FDA-approved LAP-BAND System, the investigational ReShape Vest System, the Obalon Balloon System, and the ReShapeCare virtual coaching program. This positioned the company against established surgical alternatives such as gastric bypass and sleeve gastrectomy, with a differentiation based on minimally invasive or reversible interventions that aim to avoid permanent anatomical changes. The company also pursued a broader rehabilitation position through distribution agreements for AI-driven neurorehabilitation and neuromuscular devices. However, the available comparable-company information is limited and does not identify a reliable peer set beyond ReShape itself. The competitive challenge was therefore substantial: ReShape had to demonstrate clinical adoption and commercial scale against established bariatric-device manufacturers while also funding development of its diabetes neuromodulation platform. Its $194.4 million cumulative funding figure reflects significant capital formation, but the 2025 cost reductions, delisting, and subsequent merger indicate that market position remained commercially fragile.

ReShape Lifesciences shows a long, capital-intensive medical-device trajectory with an important shift from pure bariatric products toward neuromodulation and rehabilitation. Founded in 2002, it became public in 2007 and accumulated $194.4 million across 19 recorded funding rounds. The largest listed financing was a $46.0 million post-IPO equity round in 2021, followed by $10.2 million in 2023 and two smaller offerings totaling $8.6 million in 2025. Product development included the Lap-Band 2.0 FLEX launch in early 2024 and Health Canada approval announced on Nov 12, 2024. During 2025, distribution agreements broadened the commercial footprint into Canada and U.S. rehabilitation markets, while patents in Israel and Australia strengthened the diabetes neuromodulation program. These expansion efforts coincided with operating deterioration: strategic cost reductions and workforce reductions were announced on Jun 26, 2025, and the company was delisted in August 2025. The merger with Vyome Therapeutics completed that month, marking the decisive inflection point from an independent public medical-device company to a business integrated into a new corporate structure.